Meet Shalabh Gupta, CEO of Unicycive Therapeutics (NASDAQ: UNCY)

We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, we have two programs focused on kidney disease that we believe have the potential to offer medical benefit. As we grow the Company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our current development programs are focused on the development of two novel therapies: Oxylanthanum Carbonate (OLC), for the treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494 for the treatment of acute kidney injury. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Unicycive Therapeutics (UNCY) is a client of RedChip Companies, Inc. UNCY agreed to pay RedChip Companies, Inc., a $10,000 monthly cash fee, beginning in October 2022, and 33,500 shares of Rule 144 stock, deemed earned immediately, for four months of RedChip investor awareness services.   For full disclosure, visit RedChip.com/disclosures.